查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048064

碳度巴市場 - 全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局，2021-2031年

Carbidopa Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球碳度巴市場預計將從 2025 年的 4.3489 億美元成長到 2031 年的 6.7794 億美元，複合年成長率達到 7.68%。

碳度巴是一種外周脫羧酶抑制劑，通常與左旋多巴聯合使用，透過阻止左旋多巴在血液中的分解來治療帕金森氏症。這種作用機制使得更高濃度的藥物能夠到達腦部並轉化為多巴胺，從而有效控制運動症狀。全球人口快速老化以及隨之而來的神經退化性疾病的增加，是推動該市場擴張的根本原因。例如，根據英國帕金森氏症協會預測，到2025年，英國將有約16.6萬人被診斷出患有帕金森氏症，這凸顯了需要持續多巴胺替代療法的患者群體正在擴大。

市場概覽
預測期 2027-2031
市場規模：2025年 4.3489億美元
市場規模：2031年 6.7794億美元
複合年成長率：2026-2031年 7.68%
成長最快的細分市場 間接
最大的市場 北美洲

然而，由於標準口服製劑的長期臨床局限性，市場面臨許多障礙。長期使用往往會導致藥效動力學變異和運動障礙，導致醫師經常延遲治療或將患者轉為其他腸外給藥途徑。這項臨床挑戰限制了傳統口服製劑的持續效用，並阻礙了依賴標準速釋產品的製造商的銷售量成長。

市場促進因素

帕金森氏症在全球範圍內的日益普及是市場擴張的主要驅動力，這催生了對可擴展治療方案的需求，以滿足不斷成長的患者群體。隨著預期壽命的延長，老化與神經退化性疾病進展之間的密切關聯推動了對碳度巴（多巴胺能療法的基礎藥物）的持續需求。這種人口結構的變化正在迅速擴大需要慢性病管理的患者群體，從根本上增加了全球對治療藥物的需求。根據《英國醫學雜誌》（BMJ）報道，一項2025年3月的建模研究預測，到2050年，全球帕金森氏症患者人數將達到2520萬，比2021年成長112%。疾病的經濟規模進一步加劇了這種需求的成長。帕金森氏症基金會估計，到2025年，光是在美國，帕金森氏症的直接和間接總合就將達到每年約615億美元，這凸顯了藥物干預領域巨大的市場機會。

同時，碳度巴藥物遞送技術的進步為該領域注入了新的活力，克服了傳統口服藥片生物利用度不足的限制。藥廠正積極研發皮下緩釋輸注系統和緩釋膠囊，以減輕運動症狀的波動，進而延長碳度巴製劑的商業性生命週期。由於這些創新技術能夠更有效地控制症狀，醫生們擴大選擇使用這些高品質的遞送系統，而非非專利的通用製劑。例如，2024年10月，艾伯維公司在其新核准的皮下注射療法Vyalev的大型3期臨床試驗中報告稱，與口服速釋碳度巴/左旋多巴相比，患者每天的「開」期平均增加了2.72小時，且未出現令人困擾的運動障礙。這些技術突破不僅提高了病患的依從性，也透過為新型遞送機制提供更高的定價依據，提升了市場價值。

市場挑戰

全球碳度巴市場面臨的主要挑戰之一是長期使用標準口服製劑的臨床局限性，特別是運動變異性和運動障礙的發生。儘管口服碳度巴和左旋多巴仍然是標準治療方案，但長期服用往往會導致血漿濃度不穩定。這種藥物動力學不穩定會導致「藥效減退」現象和不自主運動，常常迫使醫師限制劑量、延遲治療開始時間或將患者轉為腸外給藥。因此，傳統速釋製劑的持續效用受到影響，直接限制了大眾市場口服製劑的銷售量成長。

由於標準劑量難以持續有效控制症狀，隨著疾病進展，疾病管理變得異常複雜。管理這些晚期運動併發症帶來的巨大經濟和營運成本，凸顯了標準口服療法無效時醫療保健系統面臨的沉重負擔。帕金森氏症基金會估計，到2025年，光是在美國，帕金森氏症的直接和間接總合就將接近615億美元。如此巨大的經濟負擔凸顯了傳統口服療法功能缺陷所造成的顯著市場摩擦，這限制了產品生命週期的潛力，並阻礙了標準碳度巴市場的整體擴張。

市場趨勢

緩釋口服給藥技術的出現，從根本上改變了全球碳度巴市場，它無需侵入性操作即可解決傳統速釋製劑藥物動力學不穩定的問題。製藥公司正日益重視將速釋顆粒與緩釋丸結合的新型口服給藥系統，以確保快速緩解症狀並維持持久的療效。這項創新彌合了標準片劑和持續輸注療法之間的差距，為患者提供了一種無需侵入性操作即可減少給藥頻率的選擇。在10月舉行的2025年第三季財報電話會議上，Amneal Pharmaceuticals預測其新核准的序貫釋放碳度巴製劑Crexont在美國的銷售高峰將達到3億至5億美元，凸顯了這些先進口服技術的巨大商業性潛力。

同時，固定劑量三合一聯合治療的商業化進程正在推進，透過將兒茶酚-O-甲基轉移酵素（COMT）抑制劑與碳度巴和左旋多巴直接結合，擴大了市場範圍。這些綜合製劑旨在延長左旋多巴的半衰期並平穩血漿濃度波動，為患有嚴重運動併發症的患者提供強效解決方案。這一趨勢的特點是，全球正在部署先進的給藥機制，將這三種藥物結合起來，以最佳化多巴胺能療效。例如，STADA公司在2025年3月的公司報告中指出，其三聯療法Lecigon已在19個國家上市，並已用於治療超過1700名患者，這凸顯了定量配製方案的日益普及，這些方案簡化了複雜的治療流程。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球碳度巴市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 依應用領域（特發性巴金森氏症、腦炎後巴金森氏症候群、症狀性巴金森氏症候群、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美碳度巴市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲碳度巴市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區碳度巴市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章： 碳度巴的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章： 碳度巴的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球碳度巴市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Zydus Cadila Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28246

The Global Carbidopa Market is projected to grow from USD 434.89 Million in 2025 to USD 677.94 Million by 2031, achieving a 7.68% CAGR. Carbidopa, a peripheral decarboxylase inhibitor, is administered alongside levodopa to treat Parkinson's disease by preventing levodopa's breakdown in the bloodstream. This mechanism ensures a higher concentration of the therapeutic agent reaches the brain for conversion into dopamine, effectively managing motor symptoms. Market expansion is fundamentally supported by the rapidly aging global population and the concurrent rise in neurodegenerative disorders. For instance, Parkinson's UK reported approximately 166,000 individuals diagnosed with the condition in the United Kingdom in 2025, highlighting a growing patient pool requiring consistent dopaminergic replacement therapy.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 434.89 Million
Market Size 2031USD 677.94 Million
CAGR 2026-20317.68%
Fastest Growing SegmentIndirect
Largest MarketNorth America

However, the market faces a significant impediment due to the long-term clinical limitations of standard oral formulations. Chronic usage frequently leads to motor fluctuations and dyskinesia, often causing physicians to delay treatment initiation or switch patients to alternative non-oral delivery systems. This clinical challenge limits the sustained utility of traditional oral dosage forms and creates a barrier to volume growth for manufacturers relying on standard immediate-release products.

Market Driver

The rising global prevalence of Parkinson's disease serves as the primary engine for market expansion, necessitating scalable therapeutic solutions for an expanding demographic. As life expectancy increases, the strong correlation between advanced age and neurodegenerative decline drives sustained demand for carbidopa as a cornerstone of dopaminergic therapy. This demographic shift creates a rapidly growing patient base requiring chronic disease management, fundamentally increasing the volume of therapeutics needed globally. According to The BMJ, a March 2025 modeling study projected global Parkinson's disease cases to reach 25.2 million by 2050, a 112% increase from 2021 levels. This volume growth is further compounded by the condition's economic scale; in 2025, the Parkinson's Foundation estimated the combined direct and indirect cost of Parkinson's disease in the United States alone to be nearly $61.5 billion annually, underscoring the immense market opportunity for pharmaceutical interventions.

Concurrently, advancements in carbidopa drug delivery technologies are revitalizing the sector by addressing the bioavailability limitations of conventional oral tablets. Manufacturers are aggressively developing continuous subcutaneous infusion systems and extended-release capsules to mitigate motor fluctuations, thereby extending the commercial lifecycle of carbidopa formulations. These innovations offer superior symptom control, encouraging physicians to prescribe these premium delivery systems over generic immediate-release options. For example, AbbVie reported in October 2024 that the pivotal Phase 3 trial for the newly approved subcutaneous therapy Vyalev demonstrated patients experienced an increase of 2.72 hours in average daily "on" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa. Such technological breakthroughs not only improve patient adherence but also drive market value by justifying higher pricing tiers for novel delivery mechanisms.

Market Challenge

A significant challenge impeding the Global Carbidopa Market is the clinical limitation associated with the long-term use of standard oral formulations, specifically the development of motor fluctuations and dyskinesia. While oral carbidopa-levodopa remains the standard of care, chronic administration often results in unstable plasma concentrations. This pharmacokinetic instability causes "wearing-off" effects and involuntary movements, often compelling physicians to restrict dosage, delay treatment initiation, or switch patients to alternative non-oral delivery systems. Consequently, the sustained utility of traditional immediate-release products is compromised, directly creating a bottleneck for volume growth in the mass-market oral segment.

This inability of standard dosage forms to provide consistent symptom control significantly complicates disease management as the condition progresses. The profound economic and operational impact of managing these advanced motor complications reflects a broader strain on healthcare systems when standard oral therapies fail. The Parkinson's Foundation estimated in 2025 that the combined direct and indirect cost of Parkinson's disease in the U.S. alone rose to nearly $61.5 billion. This substantial economic burden highlights the critical market friction caused by the functional inadequacies of conventional oral therapies, which limits their lifecycle potential and hampers the overall expansion of the standard carbidopa sector.

Market Trends

The emergence of sequential-release oral dosage technologies is fundamentally altering the Global Carbidopa Market by addressing the pharmacokinetic instability of traditional immediate-release formulations without necessitating invasive procedures. Manufacturers are increasingly prioritizing novel oral delivery systems that combine immediate-release granules with extended-release pellets to ensure rapid symptom relief alongside prolonged therapeutic coverage. This innovation bridges the gap between standard pills and continuous infusion therapies, offering patients a non-invasive option to reduce dosing frequency. According to Amneal Pharmaceuticals, during its October 2025 'Q3 2025 Earnings Call', the company projected peak U.S. sales of $300 million to $500 million for Crexont, its newly approved sequential-release carbidopa formulation, underscoring the substantial commercial potential of these advanced oral technologies.

Concurrently, the commercialization of fixed-dose triple combination therapies is expanding the market's scope by integrating catechol-O-methyltransferase (COMT) inhibitors directly with carbidopa and levodopa. These comprehensive formulations are designed to extend the half-life of levodopa and smooth out plasma fluctuations, providing a robust solution for patients with advanced motor complications. This trend is characterized by the global rollout of sophisticated delivery mechanisms that combine these three agents to optimize dopaminergic efficacy. For instance, STADA reported in its March 2025 'Company Presentation' that its triple-combination therapy, Lecigon, had successfully launched in 19 countries and reached more than 1,700 patients, highlighting the growing adoption of fixed-dose regimens that streamline complex treatment protocols.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Zydus Cadila Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC

Report Scope

In this report, the Global Carbidopa Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbidopa Market, By Sales Channel

  • Direct
  • Indirect

Carbidopa Market, By End Use

  • Idiopathic Parkinson Disease
  • Postencephalitic Parkinsonism
  • Symptomatic Parkinsonism
  • Others

Carbidopa Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carbidopa Market.

Available Customizations:

Global Carbidopa Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Carbidopa Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Idiopathic Parkinson Disease, Postencephalitic Parkinsonism, Symptomatic Parkinsonism, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Carbidopa Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Carbidopa Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Carbidopa Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Carbidopa Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Carbidopa Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Carbidopa Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Carbidopa Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Carbidopa Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Carbidopa Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Carbidopa Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Carbidopa Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Carbidopa Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Carbidopa Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Carbidopa Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Carbidopa Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Carbidopa Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Carbidopa Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Carbidopa Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Carbidopa Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Carbidopa Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Carbidopa Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Carbidopa Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Carbidopa Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Carbidopa Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Carbidopa Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Mylan N.V.
  • 15.4. Sun Pharmaceutical Industries Ltd.
  • 15.5. Cipla Limited
  • 15.6. Apotex Inc.
  • 15.7. Aurobindo Pharma Ltd.
  • 15.8. Zydus Cadila Ltd.
  • 15.9. Torrent Pharmaceuticals Ltd.
  • 15.10. Hikma Pharmaceuticals PLC

16. Strategic Recommendations

17. About Us & Disclaimer